A positive dynamics driven by innovation and partnerships

EVEON carried out many innovative projects in 2020. This new year is also promising for the company driven forward by this positive dynamics.

In spite of the unusual and complicated circumstances caused by the pandemic, EVEON maintained its activities and reconfirmed its commitment to its clients with one ambition: to be a leading player so that molecules and new medicines with complex preparation or administration (lyophilisate to be reconstituted, dispersing powder, suspensions, dilutions, emulsions, combinations of therapies, highly viscous formulations, etc.) may be easily available to the greatest number of people.In spite of the unusual and complicated circumstances caused by the pandemic, EVEON maintained its activities and reconfirmed its commitment to its clients with one ambition: to be a leading player so that molecules and new medicines with complex preparation or administration (lyophilisate to be reconstituted, dispersing powder, suspensions, dilutions, emulsions, combinations of therapies, highly viscous formulations, etc.) may be easily available to the greatest number of people.

EVEON designs, develops, and assembles automated, secure, connected medical for the preparation and administration of drugs. The company provides tailored solutions thanks to a unique technological platform, Intuity®, for homecare or professional care. The platforms developed by EVEON can also be used to split doses of drugs in liquid form and perform multi-dose administrations using a single vial, an important issue.
Automation reduces the number of steps, avoids any handling of the product, and ensures homogeneity of the drug. Rquelque soit l’utilisegardless of the type of user, a patient or a healthcare professional, the preparation process is safe, reliable, and reproducible. These innovative devices can also include connectivity features to improve compliance.

Boosted by its development, EVEON has designed an automated spray device, Intuity® Spray, based on its patented technologies. This airless spray nozzle device can be used for topical or mucosal administration of formulations, including those with high viscosity. A video was recently released to highlight the key features and advantages of this new device, which supplements the range of EVEON platforms.

“In 2020, thanks to the confidence of our clients and the mobilisation of our teams, we stayed focused on our goals and maintained a very high level of service in this unprecedented context. We reached new milestones and accelerated the development of innovative medical devices. In 2021, we plan to further strengthen our process and our technological expertise in order to rapidly deliver these new devices to market,” declared Vincent Tempelaere, CEO of EVEON.

downloadFor more information, download the full press release.